Skip to content

ANI Pharmaceuticals ANIP Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$311.21M+108%$285.62M+97.1%$262.65M+81.1%$217.83M-9.3%$149.84M-34.5%
$255.43M+15.9%$281.08M+26.8%$252.62M+28.6%$225.65M+35.9%$220.33M+27.8%
$143.47M+4.4%$143.07M+4.6%$146.48M-1.1%$138.32M+10.3%$137.41M+20.7%
$747.08M+39.3%$753.12M+42.5%$698.4M+34.0%$602.63M+8.5%$536.29M-0.8%
$67.12M+15.4%$62.48M+9.9%$63.56M+12.1%$59.25M+14.7%$58.18M+19.9%
$62.48M+3.0%$62.48M+4.2%$62.48M+3.4%$60.53M+114%$60.66M+115%
$467.16M-10.6%$479.53M-11.5%$499.82M-9.1%$520.32M+219%$522.7M+197%
$1.42B+10.0%$1.44B+12.1%$1.41B+9.4%$1.34B+45.9%$1.29B+41.3%
$69.69M+31.4%$62.58M+37.1%$69.8M+14.6%$54.57M+12.1%$53.06M+7.3%
$19.3M+72.4%$17.27M+88.3%$15.24M+113%$13.22M+1,455%$11.19M+1,217%
$239.51M+18.7%$278.11M+43.0%$270.56M+42.4%$236.84M+69.2%$201.82M+47.4%
$286M-6.3%$291.84M-5.6%$297.68M-4.9%$301.48M+6.0%$305.29M+7.3%
$859.67M+1.3%$899.65M+5.1%$902.34M+5.3%$881.39M+100%$848.96M+94.0%
$3K+50.0%$3K+50.0%$3K+50.0%$2K0.0%$2K0.0%
$6.39M+108%-$23.1M+77.0%-$50.59M+43.5%-$76.86M-18.2%-$85M-36.4%
$562.3M+34.3%$540.72M+33.9%$505.82M+24.6%$436.76M-4.2%$418.62M-7.4%
$1.42B+10.0%$1.44B+12.1%$1.41B+9.4%$1.34B+45.9%$1.29B+41.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ANI Pharmaceuticals's total assets?
ANI Pharmaceuticals (ANIP) holds $1.4B in total assets, up 10.0% year over year.
How much debt does ANI Pharmaceuticals have?
ANI Pharmaceuticals carries $305.3M in total debt against $562.3M of shareholders' equity, a debt-to-equity ratio of 0.54.
How much cash does ANI Pharmaceuticals have?
ANI Pharmaceuticals holds $311.2M in cash and equivalents.
Can ANI Pharmaceuticals cover its short-term obligations?
Its current ratio is 3.12 — current assets exceed current liabilities.
Where does ANI Pharmaceuticals's balance sheet data come from?
Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.